Penumbra Inc (PEN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Penumbra Inc (PEN) has a cash flow conversion efficiency ratio of 0.043x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($58.26 Million) by net assets ($1.36 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Penumbra Inc - Cash Flow Conversion Efficiency Trend (2013–2024)
This chart illustrates how Penumbra Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read PEN liabilities breakdown for a breakdown of total debt and financial obligations.
Penumbra Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Penumbra Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
VERBUND AG
VI:VER
|
0.075x |
|
Sinopac Financial Holdings Co Ltd
TW:2890
|
0.289x |
|
Fox Corp Class B
NASDAQ:FOX
|
-0.060x |
|
Solstice Advanced Materials, Inc
NASDAQ:SOLS
|
0.121x |
|
Synnex Corporation
NYSE:SNX
|
0.173x |
|
McCormick & Company Incorporated
NYSE:MKC
|
0.094x |
|
KT&G Corp
KO:033780
|
0.030x |
|
COLOPLAST SP.ADR 1/10 DK1
F:CBH
|
0.162x |
Annual Cash Flow Conversion Efficiency for Penumbra Inc (2013–2024)
The table below shows the annual cash flow conversion efficiency of Penumbra Inc from 2013 to 2024. For the full company profile with market capitalisation and key ratios, see market cap of Penumbra Inc.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $1.15 Billion | $168.48 Million | 0.146x | +77.31% |
| 2023-12-31 | $1.18 Billion | $97.33 Million | 0.083x | +248.16% |
| 2022-12-31 | $998.86 Million | $-55.66 Million | -0.056x | -659.43% |
| 2021-12-31 | $953.93 Million | $9.50 Million | 0.010x | +119.11% |
| 2020-12-31 | $637.79 Million | $-33.24 Million | -0.052x | -194.97% |
| 2019-12-31 | $485.61 Million | $26.65 Million | 0.055x | -19.52% |
| 2018-12-31 | $422.42 Million | $28.81 Million | 0.068x | +115.17% |
| 2017-12-31 | $400.41 Million | $12.69 Million | 0.032x | +165.97% |
| 2016-12-31 | $266.55 Million | $-12.81 Million | -0.048x | +49.85% |
| 2015-12-31 | $232.52 Million | $-22.28 Million | -0.096x | -118.55% |
| 2014-12-31 | $-12.37 Million | $-6.39 Million | 0.516x | +22.61% |
| 2013-12-31 | $-8.06 Million | $-3.40 Million | 0.421x | -- |
About Penumbra Inc
Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral thrombectomy products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also… Read more